Record overview
Status and phase
Status: RECRUITING
Phase: PHASE1, PHASE2
Sponsor: Merck Sharp & Dohme LLC
Condition: Malignant Neoplasm
NCT06941272
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: None
Stopped reason
Context when available
No stop reason available in the current public record.